Therapeutic Solutions International Continues to Refine
NanoStilbene™ Formulation
NanoStilbene Shown to Reduce Tumor Necrosis Factor-α (TNF-α
) in Cancer Patients
OCEANSIDE, CA -- February 19, 2019 -- InvestorsHub
NewsWire -- Therapeutics Solutions International, Inc., (OTC
Markets:
TSOI) announced today further refinement of
their patented formulation of nanoparticle pterostilbene known as
NanoStilbene™.
NanoStilbene™ is a nanoemulsion of nanoparticle
pterostilbene in the 75-90nm (nanometer) range at a concentration
of 200mg per milliliter. We have successfully produced the same
stable nanoemulsion using peach kernel extract to fortify the
NanoStilbene against tumor necrosis factor-α (TNF-α ).
"We recently announced the conclusion of a
clinical trial involving 12 advanced, solid tumor, cancer patients
who received the equivalence of 300mg's of nanoparticle
pterostilbene daily for three weeks which showed on average a 26%
decrease in TNF-α 1," said Tim G Dixon CEO
& President of Therapeutic Solutions International, Inc. "By
adding peach kernel extract to our nanoemulsion formulation we
intend to fortify NanoStilbene to be even more effective against
high levels of inflammatory cytokines."
"In a recent paper, peach kernel
extract has been shown to reduce tissue factor (TF) elevations in
atherosclerosis, which is a pathological process in arteries due to
plaque formation, by first reducing tumor necrosis factor-α
(TNF-α)2," said Dr. Thomas Ichim, Director of
Therapeutic Solutions International. "Tumor necrosis factor (TNF)
is a type of messenger protein known as a cytokine that is produced
by white blood cells. It promotes inflammation, produces other
cells used in the inflammatory response, and can help cells heal"
added Dr. Ichim.
"By adding the peach kernel extract to the
nanoemulsion formulation, our purpose is to open the way for new
therapeutic approaches that might eventually decrease the
prevalence of tumor necrosis factor-α (TNF-α) in not
only cancer patients where TNF-α has been shown to play a key role
in these inflammatory processes but also in acute and chronic
inflammatory conditions such as trauma, sepsis, infection,
rheumatoid arthritis, atherosclerosis, and cardiovascular disease"
said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic
Solutions International.
TNF-α is a member of a
growing family of peptide mediators comprising at least 19
cytokines, including lymphotoxin-, Fas ligand, and CD40 ligand.
TNF-α has important proinflammatory properties, which play crucial
roles in the innate and adaptive immunity, cell proliferation, and
apoptotic processes. The cytokine is produced by different kind of
cells, including macrophages, monocytes, T-cells, smooth muscle
cells, adipocytes, and fibroblasts.
About Therapeutic
Solutions International, Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
at
www.therapeuticsolutionsint.com
and our
e-commerce is at www.youcanordernow.com
and for
additional info on NanoStilbene visit www.nanostilbene.com.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
1
https://nanostilbene.com/?page_id=301
2
https://www.ncbi.nlm.nih.gov/pubmed/30669336
Safe Harbor
Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
Contact
Information:
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Sep 2023 to Sep 2024